Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18886134 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | September 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18820652 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | March 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18821068 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18820609 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18821057 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18796740 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18777787 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | July 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18777187 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18757141 | AAV CAPSID VARIANTS AND USES THEREOF | June 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18649317 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | April 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18620748 | Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias | March 2024 | October 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18583147 | CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION | February 2024 | July 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18413653 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | January 2024 | June 2024 | Allow | 5 | 1 | 0 | No | No |
| 18560539 | THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR BONE AND SOFT TISSUE TUMORS | November 2023 | January 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18485178 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | October 2023 | May 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18550503 | SMART EXOSOMES FOR ACTIVE PDAC TARGETING AND EVADING MONONUCLEAR PHAGOCYTOTIC SYSTEM | September 2023 | May 2024 | Allow | 8 | 1 | 0 | No | No |
| 18458744 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18458752 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | August 2023 | May 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18318566 | CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION | May 2023 | July 2024 | Allow | 14 | 5 | 0 | Yes | No |
| 18295159 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY | April 2023 | December 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18295150 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY | April 2023 | December 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18295152 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY | April 2023 | December 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18185656 | GENE THERAPY VECTOR WITH MINIMIZING RECOMBINATION, RECOMBINANT RETROVIRUS COMPRISING THE VECTOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE RECOMBINANT RETROVIRUS | March 2023 | February 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18065580 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | December 2022 | May 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 17929165 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | September 2022 | February 2024 | Allow | 18 | 3 | 0 | Yes | No |
| 17819909 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | August 2022 | March 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 17819214 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | August 2022 | January 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 17819219 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | August 2022 | January 2024 | Allow | 18 | 2 | 0 | No | No |
| 17812425 | VECTOR AND METHOD FOR TREATING BIETTI'S CRYSTALLINE DYSTROPHY | July 2022 | April 2024 | Allow | 22 | 3 | 0 | No | No |
| 17808873 | ENCAPSULATION AND CARDIAC DIFFERENTIATION OF hiPSCs IN 3D PEG-FIBRINOGEN HYDROGELS | June 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17832196 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY | June 2022 | February 2024 | Allow | 20 | 4 | 0 | Yes | No |
| 17707725 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | March 2022 | June 2024 | Allow | 27 | 1 | 0 | No | No |
| 17697841 | METHODS FOR DISTRIBUTING HIGH LEVELS OF THERAPEUTIC AGENT THROUGHOUT THE CORTEX TO TREAT NEUROLOGICAL DISORDERS | March 2022 | March 2025 | Allow | 36 | 1 | 0 | No | No |
| 17691518 | Compositions Comprising Citrate and Applications Thereof | March 2022 | July 2024 | Allow | 28 | 1 | 1 | No | No |
| 17688782 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | March 2022 | October 2024 | Allow | 31 | 1 | 0 | No | No |
| 17627165 | RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS (RAAV) HAVING IMPROVED PACKAGING EFFICIENCY | January 2022 | July 2024 | Allow | 30 | 1 | 0 | No | No |
| 17576550 | CRISSCROSS COOPERATIVE SELF-ASSEMBLY | January 2022 | February 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17573442 | ANTI-ARRHYTHMICITY AGENTS | January 2022 | March 2025 | Allow | 38 | 1 | 0 | No | No |
| 17556847 | COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION IN CONE CELLS | December 2021 | December 2024 | Allow | 36 | 3 | 0 | No | No |
| 17555233 | DYSTROPHIN R16/R17 SYNTROPHIN PDZ FUSION PROTEINS | December 2021 | March 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17619178 | PROTEIN-BASED RESINS FOR ADDITIVE MANUFACTURING | December 2021 | August 2024 | Allow | 32 | 1 | 1 | No | No |
| 17546183 | DESIGN OF BACTERIOPHAGE-BASED ARTIFICIAL VIRUSES FOR HUMAN GENOME REMODELING | December 2021 | November 2024 | Allow | 35 | 1 | 0 | No | No |
| 17527766 | BRANCHED RECEPTOR BINDING MULTI-SUBUNIT PROTEIN COMPLEXES FOR USE IN BACTERIAL DELIVERY VEHICLES | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17522284 | IMMUNOLOGIC EFFECTOR CELL OF TARGETED CLD18A2, AND PREPARATION METHOD AND USE THEREOF | November 2021 | June 2024 | Allow | 31 | 1 | 0 | No | No |
| 17450544 | COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE | October 2021 | November 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17488542 | PROKARYOTIC-EUKARYOTIC HYBRID VIRAL VECTOR FOR DELIVERY OF LARGE CARGOS OF GENES AND PROTEINS INTO HUMAN CELLS | September 2021 | April 2024 | Allow | 31 | 2 | 0 | No | No |
| 17459095 | HIGH THROUGHPUT ASSAY FOR MEASURING ADENOVIRUS REPLICATION KINETICS | August 2021 | May 2024 | Allow | 33 | 1 | 0 | No | No |
| 17412592 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | August 2021 | April 2025 | Allow | 43 | 1 | 1 | No | No |
| 17458083 | METHODS OF PREPARING AND USING NOVEL STEM CELL COMPOSITIONS AND KITS COMPRISING THE SAME | August 2021 | May 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17400467 | IMMUNE CELL FUNCTION | August 2021 | June 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17393362 | POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT | August 2021 | July 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17391862 | MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP) | August 2021 | June 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17378580 | NUCLEIC ACID THERAPEUTICS FOR GENETIC DISORDERS | July 2021 | April 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17369831 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | July 2021 | December 2024 | Allow | 41 | 1 | 1 | No | No |
| 17367619 | Microfluidic Delivery Method Utilizing An Electric Field | July 2021 | April 2024 | Allow | 33 | 2 | 0 | No | No |
| 17366708 | Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target Tumors | July 2021 | February 2024 | Allow | 31 | 1 | 0 | No | No |
| 17360578 | MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A | June 2021 | September 2024 | Allow | 39 | 2 | 0 | No | No |
| 17355325 | LINKED PERFUSION TO CONTINUOUS-FLOW STIRRED-TANK REACTOR CELL CULTURE SYSTEM | June 2021 | September 2024 | Allow | 39 | 1 | 1 | No | No |
| 17350769 | METHODS FOR EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES IN VITRO AND IN VIVO | June 2021 | May 2024 | Allow | 35 | 1 | 0 | No | No |
| 17337744 | IMMUNOADSORPTION | June 2021 | July 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17337177 | DELIVERY ACROSS CELL PLASMA MEMBRANES | June 2021 | August 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17334953 | GENETICALLY ENGINEERED GAS VESICLE GENE CLUSTERS, GENETIC CIRCUITS, VECTORS, PROKARYOTIC CELLS, COMPOSITIONS, METHODS AND SYSTEMS FOR CONTRAST-ENHANCED IMAGING | May 2021 | September 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 17333904 | RECOMBINANT INFLUENZA VIRUSES AND CONSTRUCTS AND USES THEREOF | May 2021 | May 2024 | Allow | 36 | 2 | 0 | No | No |
| 17331884 | Functionalized Erythroid Cells | May 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17296944 | GENE THERAPY OF HEMOPHILIA A USING VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION | May 2021 | May 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17322561 | Genome Editing without Nucleases | May 2021 | December 2023 | Allow | 31 | 1 | 0 | No | No |
| 17316749 | LIPOSOMAL COMPOSITIONS AND USES OF SAME | May 2021 | March 2024 | Allow | 34 | 1 | 0 | No | No |
| 17290927 | OPTIMIZED FIG4 GENES AND EXPRESSION CASSETTES AND THEIR USE | May 2021 | February 2025 | Allow | 46 | 2 | 1 | No | No |
| 17290082 | A CODON OPTIMIZED OTOFERLIN AAV DUAL VECTOR GENE THERAPY | April 2021 | August 2024 | Allow | 40 | 1 | 0 | No | No |
| 17239131 | LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF MRNA | April 2021 | December 2024 | Allow | 44 | 2 | 0 | No | Yes |
| 17238743 | METHODS OF HEAT INACTIVATION OF ADENOVIRUS | April 2021 | November 2023 | Allow | 31 | 1 | 0 | No | No |
| 17222442 | POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | April 2021 | March 2024 | Allow | 35 | 1 | 0 | No | No |
| 17280384 | CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION | March 2021 | July 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 17212484 | ENGINEERED CHIMERIC NUCLEIC ACID GUIDED NUCLEASE CONSTRUCTS AND USES THEREOF | March 2021 | November 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17277452 | PEG LIPIDS AND USES THEREOF | March 2021 | July 2024 | Allow | 40 | 0 | 1 | No | No |
| 17277183 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | March 2021 | February 2025 | Allow | 47 | 2 | 0 | No | No |
| 17201036 | HUMAN TROPHOBLAST STEM CELLS AND USES THEREOF | March 2021 | April 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17175117 | Metakaryocidal Treatments | February 2021 | June 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17167743 | Adeno-Associated-Virus Rep Sequences, Vectors and Viruses | February 2021 | July 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17161803 | USE OF LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY TO CHARACTERIZE OLIGONUCLEOTIDES | January 2021 | May 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17160952 | Method of Manufacturing Dual Specific T-Cells for Use in Cancer Immunotherapy | January 2021 | January 2024 | Allow | 36 | 1 | 0 | No | No |
| 17154050 | ARTIFICIAL EXOSOME COMPOSITION AND RELATED METHODS | January 2021 | February 2024 | Allow | 37 | 2 | 0 | No | No |
| 17145848 | PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS | January 2021 | April 2024 | Allow | 39 | 2 | 0 | No | No |
| 17146024 | Transgenic Macrophages, Chimeric Antigen Receptors, and Associated Methods | January 2021 | January 2024 | Allow | 36 | 2 | 0 | No | No |
| 17258316 | FUSOSOME COMPOSITIONS AND USES THEREOF | January 2021 | February 2025 | Allow | 49 | 2 | 1 | No | No |
| 17141753 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | January 2021 | October 2023 | Allow | 33 | 1 | 0 | No | No |
| 17127435 | TERMINALLY MODIFIED RNA | December 2020 | December 2023 | Allow | 36 | 1 | 0 | No | No |
| 17254001 | NUCLEIC ACID CONSTRUCT | December 2020 | February 2024 | Allow | 38 | 1 | 0 | No | No |
| 17125885 | Method of Reducing Titers of Antibodies Specific for a Therapeutic Agent | December 2020 | December 2024 | Allow | 48 | 2 | 0 | No | No |
| 17253606 | CORRECTION OF DYSTROPHIN EXON 43, EXON 45, OR EXON 52 DELETIONS IN DUCHENNE MUSCULAR DYSTROPHY | December 2020 | June 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17252818 | SUPERNATANT FROM A COCULTURE OF MACROPHAGES AND IRRADIATED LEUKOCYTES, FOR CONTROLLING TUMOUR PROGRESSION OR RESTORING ANTI-TUMOR IMMUNITY | December 2020 | July 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17117661 | GENETIC MODIFICATION OF RATS | December 2020 | April 2024 | Allow | 40 | 2 | 0 | No | No |
| 17117981 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | December 2020 | January 2024 | Allow | 38 | 2 | 0 | No | No |
| 17057346 | ADENO-ASSOCIATED VIRAL VECTOR-MEDIATED GENE THERAPY FOR TREATING FRAGILE X-ASSOCIATED DISORDERS | November 2020 | January 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17041061 | POPULATION OF CD3-NEGATIVE CELLS THAT EXPRESS CHEMOKINE RECEPTOR AND CELL ADHESION MOLECULE, USE OF THE SAME, AND METHOD FOR PRODUCING THE SAME | October 2020 | January 2024 | Allow | 40 | 1 | 0 | No | No |
| 17038676 | COMPOSITIONS AND METHODS FOR T CELL DELIVERY OF THERAPEUTIC MOLECULES | September 2020 | September 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 17032221 | FUNCTIONAL CURE OF RETROVIRAL INFECTION | September 2020 | June 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 17010556 | COMPOSITIONS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO COCHLEAR AND VESTIBULAR CELLS | September 2020 | December 2024 | Allow | 52 | 3 | 1 | Yes | No |
| 17006629 | MEMBRANE-PENETRATING PEPTIDES TO ENHANCED TRANSFECTION AND COMPOSITIONS AND METHODS FOR USING SAME | August 2020 | November 2023 | Allow | 39 | 3 | 0 | No | No |
| 17000867 | EFFICIENT SYSTEMIC TREATMENT OF DYSTROPHIC MUSCLE PATHOLOGIES | August 2020 | April 2024 | Allow | 44 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KELLY, ROBERT M.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KELLY, ROBERT M works in Art Unit 1638 and has examined 201 patent applications in our dataset. With an allowance rate of 91.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.
Examiner KELLY, ROBERT M's allowance rate of 91.0% places them in the 74% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by KELLY, ROBERT M receive 2.37 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KELLY, ROBERT M is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +15.1% benefit to allowance rate for applications examined by KELLY, ROBERT M. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 24.7% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 57.5% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 95.2% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 95.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 43.5% are granted (fully or in part). This grant rate is in the 46% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 18.9% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.6% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.